Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Agios Pharmaceuticals, Inc. stock logo
AGIO
Agios Pharmaceuticals
$38.70
+6.7%
$32.18
$23.42
$62.58
$2.24B0.73650,331 shs152,707 shs
Alkermes plc stock logo
ALKS
Alkermes
$29.89
+1.7%
$30.16
$22.90
$36.45
$4.90B0.441.74 million shs264,591 shs
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
$114.56
+5.7%
$106.61
$72.21
$139.13
$5.60B0.46665,624 shs125,332 shs
Blueprint Medicines Corporation stock logo
BPMC
Blueprint Medicines
$128.48
+0.1%
$115.15
$73.04
$128.78
$8.30B0.891.34 million shs1.05 million shs
Genmab A/S Sponsored ADR stock logo
GMAB
Genmab A/S
$21.52
+1.3%
$21.01
$17.24
$28.56
$13.78B0.941.24 million shs242,952 shs
Ten Starter Stocks For Beginners to Buy Now Cover

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Agios Pharmaceuticals, Inc. stock logo
AGIO
Agios Pharmaceuticals
+3.04%+5.56%+5.68%+38.05%-11.92%
Alkermes plc stock logo
ALKS
Alkermes
+0.51%+1.35%-7.35%+1.98%+20.56%
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
+0.85%+5.28%-3.13%+6.63%+29.65%
Blueprint Medicines Corporation stock logo
BPMC
Blueprint Medicines
0.00%+0.05%+0.43%+56.49%+10.39%
Genmab A/S Sponsored ADR stock logo
GMAB
Genmab A/S
+3.56%+2.46%-4.28%+12.85%-16.60%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Agios Pharmaceuticals, Inc. stock logo
AGIO
Agios Pharmaceuticals
4.0693 of 5 stars
3.41.00.04.31.80.81.9
Alkermes plc stock logo
ALKS
Alkermes
4.9334 of 5 stars
4.43.00.04.23.52.51.9
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
4.7402 of 5 stars
4.51.00.04.52.44.20.6
Blueprint Medicines Corporation stock logo
BPMC
Blueprint Medicines
1.5056 of 5 stars
2.14.00.00.02.00.80.6
Genmab A/S Sponsored ADR stock logo
GMAB
Genmab A/S
4.0127 of 5 stars
3.35.00.00.02.80.03.1
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Agios Pharmaceuticals, Inc. stock logo
AGIO
Agios Pharmaceuticals
2.71
Moderate Buy$58.6051.43% Upside
Alkermes plc stock logo
ALKS
Alkermes
2.83
Moderate Buy$40.0033.84% Upside
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
3.06
Buy$172.3350.44% Upside
Blueprint Medicines Corporation stock logo
BPMC
Blueprint Medicines
2.24
Hold$128.25-0.18% Downside
Genmab A/S Sponsored ADR stock logo
GMAB
Genmab A/S
2.67
Moderate Buy$37.8075.67% Upside

Current Analyst Ratings Breakdown

Latest ALKS, BPMC, GMAB, AGIO, and AXSM Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/8/2025
Genmab A/S Sponsored ADR stock logo
GMAB
Genmab A/S
Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$45.00 ➝ $46.00
7/3/2025
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOverweight$190.00
6/17/2025
Alkermes plc stock logo
ALKS
Alkermes
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeNeutral ➝ Buy$33.00 ➝ $42.00
6/17/2025
Blueprint Medicines Corporation stock logo
BPMC
Blueprint Medicines
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeStrong-Buy ➝ Hold$143.00 ➝ $129.00
6/12/2025
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$193.00 ➝ $186.00
6/10/2025
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$180.00
6/9/2025
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$153.00 ➝ $150.00
6/5/2025
Blueprint Medicines Corporation stock logo
BPMC
Blueprint Medicines
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetEqual Weight ➝ Equal Weight$102.00 ➝ $129.00
6/5/2025
Blueprint Medicines Corporation stock logo
BPMC
Blueprint Medicines
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetNeutral ➝ Neutral$88.00 ➝ $129.00
6/4/2025
Blueprint Medicines Corporation stock logo
BPMC
Blueprint Medicines
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong Sell ➝ Hold$83.00 ➝ $129.00
6/3/2025
Blueprint Medicines Corporation stock logo
BPMC
Blueprint Medicines
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price Target$132.00
(Data available from 7/9/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Agios Pharmaceuticals, Inc. stock logo
AGIO
Agios Pharmaceuticals
$36.50M61.41N/AN/A$27.02 per share1.43
Alkermes plc stock logo
ALKS
Alkermes
$1.56B3.16$2.71 per share11.02$9.05 per share3.30
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
$385.69M14.62N/AN/A$1.18 per share97.08
Blueprint Medicines Corporation stock logo
BPMC
Blueprint Medicines
$508.82M16.31N/AN/A$4.70 per share27.34
Genmab A/S Sponsored ADR stock logo
GMAB
Genmab A/S
$3.12B4.42$1.59 per share13.53$8.04 per share2.68
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Agios Pharmaceuticals, Inc. stock logo
AGIO
Agios Pharmaceuticals
$673.72M$11.243.44N/AN/A1,798.26%-2.75%-2.52%7/30/2025 (Estimated)
Alkermes plc stock logo
ALKS
Alkermes
$367.07M$2.0914.2321.821.8223.30%27.52%17.98%7/23/2025 (Estimated)
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
-$287.22M-$5.77N/A40.62N/A-64.39%-272.80%-36.69%8/4/2025 (Estimated)
Blueprint Medicines Corporation stock logo
BPMC
Blueprint Medicines
-$67.09M-$2.47N/A197.66N/A-27.70%-64.60%-17.22%7/30/2025 (Estimated)
Genmab A/S Sponsored ADR stock logo
GMAB
Genmab A/S
$1.14B$1.7612.2112.096.6935.11%18.08%14.52%8/14/2025 (Estimated)

Latest ALKS, BPMC, GMAB, AGIO, and AXSM Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/4/2025Q2 2025
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
-$1.04N/AN/AN/A$140.02 millionN/A
7/23/2025Q2 2025
Alkermes plc stock logo
ALKS
Alkermes
$0.42N/AN/AN/A$343.20 millionN/A
5/8/2025Q1 2025
Genmab A/S Sponsored ADR stock logo
GMAB
Genmab A/S
$0.23$0.31+$0.08$0.31$5.17 billion$715.00 million
5/1/2025Q1 2025
Agios Pharmaceuticals, Inc. stock logo
AGIO
Agios Pharmaceuticals
-$1.80-$1.55+$0.25-$1.55$9.86 million$8.73 million
5/1/2025Q1 2025
Alkermes plc stock logo
ALKS
Alkermes
$0.32$0.13-$0.19$0.13$307.53 million$306.51 million
5/1/2025Q1 2025
Blueprint Medicines Corporation stock logo
BPMC
Blueprint Medicines
-$0.42-$0.74-$0.32$0.01$158.31 million$149.41 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Agios Pharmaceuticals, Inc. stock logo
AGIO
Agios Pharmaceuticals
N/AN/AN/AN/AN/A
Alkermes plc stock logo
ALKS
Alkermes
N/AN/AN/AN/AN/A
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
N/AN/AN/AN/AN/A
Blueprint Medicines Corporation stock logo
BPMC
Blueprint Medicines
N/AN/AN/AN/AN/A
Genmab A/S Sponsored ADR stock logo
GMAB
Genmab A/S
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Agios Pharmaceuticals, Inc. stock logo
AGIO
Agios Pharmaceuticals
N/A
18.50
17.93
Alkermes plc stock logo
ALKS
Alkermes
N/A
3.33
2.92
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
3.48
2.03
1.96
Blueprint Medicines Corporation stock logo
BPMC
Blueprint Medicines
1.01
2.80
2.75
Genmab A/S Sponsored ADR stock logo
GMAB
Genmab A/S
N/A
5.34
5.32

Institutional Ownership

CompanyInstitutional Ownership
Agios Pharmaceuticals, Inc. stock logo
AGIO
Agios Pharmaceuticals
N/A
Alkermes plc stock logo
ALKS
Alkermes
95.21%
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
81.49%
Blueprint Medicines Corporation stock logo
BPMC
Blueprint Medicines
N/A
Genmab A/S Sponsored ADR stock logo
GMAB
Genmab A/S
7.07%

Insider Ownership

CompanyInsider Ownership
Agios Pharmaceuticals, Inc. stock logo
AGIO
Agios Pharmaceuticals
4.93%
Alkermes plc stock logo
ALKS
Alkermes
4.40%
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
22.40%
Blueprint Medicines Corporation stock logo
BPMC
Blueprint Medicines
4.21%
Genmab A/S Sponsored ADR stock logo
GMAB
Genmab A/S
1.54%
CompanyEmployeesShares OutstandingFree FloatOptionable
Agios Pharmaceuticals, Inc. stock logo
AGIO
Agios Pharmaceuticals
39057.92 million55.06 millionOptionable
Alkermes plc stock logo
ALKS
Alkermes
1,800164.90 million157.65 millionOptionable
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
38049.24 million38.21 millionOptionable
Blueprint Medicines Corporation stock logo
BPMC
Blueprint Medicines
64064.58 million61.86 millionOptionable
Genmab A/S Sponsored ADR stock logo
GMAB
Genmab A/S
2,682641.54 million631.35 millionOptionable

Recent News About These Companies

Genmab Announces Changes to its Executive Committee
Completion of Share Buy-back Program
Transactions in Connection with Share Buy-back Program
Transactions in Connection with Share Buy-back Program

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Agios Pharmaceuticals stock logo

Agios Pharmaceuticals NASDAQ:AGIO

$38.70 +2.42 (+6.66%)
As of 11:01 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias. The company develops AG-946, a PK activator for treating lower-risk myelodysplastic syndrome and hemolytic anemias; and AG-181, a phenylalanine hydroxylase stabilizer for the treatment of phenylketonuria. Its preclinical product is siRNA for the treatment of polycythemia vera, a rare blood disorder. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.

Alkermes stock logo

Alkermes NASDAQ:ALKS

$29.89 +0.51 (+1.73%)
As of 11:01 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence; and LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. The company also offers proprietary technology platforms to third parties to enable them to develop, commercialize, and manufacture products. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.

Axsome Therapeutics stock logo

Axsome Therapeutics NASDAQ:AXSM

$114.56 +6.15 (+5.67%)
As of 11:01 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea. It is also developing AXS-05, which is in Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation; AXS-07, an investigational medicine that has completed Phase III trials for the acute treatment of migraine; AXS-12, an investigational medicine, which is in Phase III trial to treat narcolepsy; AXS-14, a selective and potent norepinephrine reuptake inhibitor that has completed Phase III trial for the treatment of fibromyalgia and other conditions; and solriamfetol, a dual-acting dopamine and norepinephrine reuptake inhibitor, which has completed a Phase 2 trial for treating attention-deficit/hyperactivity disorder, and is in phase 2 major depressive, binge eating, and shift work disorder. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York.

Blueprint Medicines stock logo

Blueprint Medicines NASDAQ:BPMC

$128.48 +0.08 (+0.06%)
As of 11:01 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders. It is also developing GAVRETO for the treatment of RET fusion-positive non-small cell lung cancer, altered thyroid carcinoma, and medullary thyroid carcinoma; BLU-945 for the treatment of epidermal growth factor receptor driven non-small-cell lung carcinoma (NSCLC); and BLU-451 to treat NSCLC in patients with epidermal growth factor receptor gene (EGFR) exon 20 insertion mutations. In addition, the company is developing BLU-782, for the treatment of fibrodysplasia ossificans progressive; BLU- 222 to treat patients with cyclin E aberrant cancers; and BLU-852 for the treatment of advanced cancers. It has collaboration and license agreements with Clementia Pharmaceuticals, Inc.; Proteovant Therapeutics; CStone Pharmaceuticals; Genentech, Inc.; Hoffmann-La Roche Inc.; and Zai Lab (Shanghai) Co., Ltd. The company was formerly known as Hoyle Pharmaceuticals, Inc. and changed its name to Blueprint Medicines Corporation in June 2011. Blueprint Medicines Corporation was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.

Genmab A/S stock logo

Genmab A/S NASDAQ:GMAB

$21.52 +0.27 (+1.26%)
As of 11:01 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and GEN3017 for treating hematological malignancies. In addition, the company develops Inclacumab, which is in Phase 3 trial for vaso-occlusive crises; Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating multiple system atrophy disease. It operates various active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with argenx to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology; and AbbVie for the development of epcoritamab, as well as collaborations with BioNTech, Janssen, and Novo Nordisk A/S. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.